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Abstract
Idiopathic CD4 lymphocytopenia (ICL) is a rare immune deficiency characterized by a protracted CD4+ T cell loss of
unknown etiology and by the occurrence of opportunistic infections similar to those seen in AIDS. We investigated whether
a defect in responses to cytokines that control CD4+ T cell homeostasis could play a role in ICL. Immunophenotype and
signaling responses to interleukin-7 (IL-7), IL-2, and thymic stromal lymphopoietin (TSLP) were analyzed by flow cytometry
in CD4+ T cells from 15 ICL patients and 15 healthy blood donors. The induction of phospho-STAT5 after IL-7 stimulation was
decreased in memory CD4+ T cells of some ICL patients, which correlated with a decreased expression of the IL-7Ra receptor
chain (R = 0.74, p,0.005) and with lower CD4+ T cell counts (R = 0.69, p,0.005). IL-2 responses were also impaired, both in
the Treg and conventional memory subsets. Decreased IL-2 responses correlated with decreased IL-7 responses (R = 0.75,
p,0.005), pointing to combined defects that may significantly perturb CD4+ T cell homeostasis in a subset of ICL patients.
Unexpectedly, responses to the IL-7-related cytokine TSLP were increased in ICL patients, while they remained barely
detectable in healthy controls. TSLP responses correlated inversely with IL-7 responses (R =20.41; p,0.05), suggesting a
cross-regulation between the two cytokine systems. In conclusion, IL-7 and IL-2 signaling are impaired in ICL, which may
account for the loss of CD4+ T cell homeostasis. Increased TSLP responses point to a compensatory homeostatic mechanism
that may mitigate defects in cc cytokine responses.
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Introduction
Idiopathic CD4+ lymphocytopenia (ICL) is an immune
deficiency characterized by persistently decreased CD4+ T
lymphocyte numbers in the absence of HIV infection or other
known causes of T cell depletion [1–8]. Clinical signs are variable,
with a subset of patients presenting with life threatening
opportunistic infections very similar to those seen in AIDS,
including Cryptococcus neoformans meningitis, disseminated Mycobac-
terium avium infection, tuberculosis, and Pneumocytis jiroveci pneumo-
nia [5,9]. ICL is most frequently diagnosed in adults [1], though
cases have also been reported in children [6–8]. Studies launched
in the early 90’s to identify a possible retrovirus associated with
ICL were inconclusive [1] and the etiology of ICL remains
unknown in most cases.
Mechanistic studies of T cell function in ICL have provided
evidence for increased immune activation and increased suscep-
tibility to apoptosis, in a process that is partially dependent on Fas
expression [10,11]. Abnormal immune activation was confirmed
by the detection of an increased T cell turnover [12] and by the
presence of microbial translocation products in the plasma of ICL
patients, similar to findings reported in HIV infection [13].
Another factor that may contribute to the loss of CD4+ T cells is a
decreased clonogenic capacity of the bone marrow in ICL patients
[14]. A hypomorphic mutation of the recombination activating
gene 1 (RAG1), which triggers TCR and immunoglobulin gene
rearrangements, was recently identified in a child with ICL [15].
Thus, the spectrum of immune defects associated with RAG
mutations may include ICL in addition to Omenn syndrome,
granulomatous disease, and severe combined immunodeficiency
[16]. A decrease in p56 Lck activity was initially reported in one
ICL case, raising the possibility of defective TCR signal
transduction [17]. This notion was recently supported by the
identification of mutations that impair but do not abrogate TCR
signaling in some ICL patients. The mutations targets the adaptor
protein uncoordinated 119 (UNC119), which is required for Lck
transport and activation [18], or the magnesium transporter 1
(MAGT1), which contributes to the proper activation of
phospholipase C gamma 1 (PLCc1) [19]. It should be noted,
however, that only a few of ICL patients show signs of impaired
TCR signaling [20].
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Depletion of the CD8+ T cell population occurs in a subset of
ICL patients and is associated with more severe disease outcome
than CD4+ T cell depletion alone [12]. The B cell compartment
also shows abnormalities, including an accumulation of imma-
ture/transitional B cells that may be driven by increased levels of
IL-7 in peripheral blood [21]. However, circulating immunoglob-
ulin levels usually remain in the normal range, and the spectrum of
opportunistic infections is indicative of T cell rather than B cell
immunodeficiency. The increase of circulating IL-7 in ICL
patients parallels that seen in HIV-infected patients with severely
depleted CD4+ T cell counts [22,23], and likely reflects a
compensatory mechanism that promotes homeostatic T cell
proliferation in response to lymphopenia. Increased availability
of IL-7 is thought to result from lower consumption of the cytokine
by a reduced T cell pool [22,24]. In addition, more recent
evidence suggest that lymphopenia also triggers an increased
production of IL-7 by stromal cells in the thymus [25] and possibly
the bone marrow [26]. Raised IL-7 concentration can then
facilitate T cell proliferation in response to self and non-self
antigens [24]. However, increased IL-7 levels do not appear
sufficient to restore the CD4+ T cell counts in ICL, raising the
possibility of downstream defects in the IL-7 response pathway.
Another indication that cytokines may be involved in ICL
pathogenesis arises from reports of a beneficial effect of IL-2
immunotherapy. Case reports suggested that recombinant IL-2
administration could raise CD4+ T cell counts in ICL patients and
help improve the clinical outcome of opportunistic infections,
including cryptococcal meningitis [6], chronic mycobacterial
disease [27,28], and relapsing herpes zoster infection [29].
Recently, we reported that IL-2 administration improved CD4+
T cell counts in three out of four treated patients [20]. In the
course of this study, we noted a markedly decreased expression of
the chemokine receptor CXCR4 at the surface of CD4+ T cells
from ICL patients, suggesting that impaired CXCR4-dependent
cell trafficking may contribute to the immunodeficiency. Impor-
tantly, CXCR4 expression was normalized in the three patients
who responded to IL-2 therapy but not in the non-responder.
Given the known capacity of cc cytokines to upregulate CXCR4
expression [30–32], one hypothesis is that defective cytokine
responses lead to decreased chemokine receptor expression in
ICL.
To explore the involvement of cytokines in ICL pathogenesis,
we tested the capacity of ICL patient cells to respond to IL-7 and
IL-2, two key cc family cytokines known to control the CD4+ T
cell pool size [33]. We also measured responses to TSLP, a
cytokine that shares structural and functional properties with IL-7,
and whose role in human T cell homeostasis remains incompletely
understood [34,35]. We found that CD4+ T cells from ICL
patients responded less efficiently to both IL-2 and IL-7. The two
defects correlated together, suggesting they may synergize in
perturbing CD4+ T cell homeostasis. Intriguingly, responses to
TSLP were increased in CD4+ T cells of ICL patients, revealing a
compensatory role for this IL-7-like cytokine.
Methods
Study design
All patients met the definition of ICL established by the Center
for Disease Control, namely the occurrence of a CD4+ T cell
count ,300 mm3 or ,20% of lymphocytes on at least two
separate measurements [1]. All patients were seronegative for
HIV-1, HIV-2, HTLV-1, HTLV-2, HBV, HCV, and HHV-8.
HIV load was undetectable in all patients and none of them had
clinical or biological evidences of active EBV infection, systemic
lupus erythematosus, Sjo¨gren syndrome, or sarcoidosis. ICL
diagnosis was confirmed after ruling out known causes of
immunodeficiency. Clinical and immunological characteristics of
the ICL patients included in the study are reported in Table 1.
Ethics statement
Fifteen adult ICL patients were recruited into the study, which
was approved by the Comite´ de Protection des Personnes de l’Ile
de France VI. All participants gave written informed consent prior
to blood sampling. Patient P9 had been previously treated with IL-
2 and did not respond to therapy. CXCR4 responses for this
patient have been previously reported (former code name: P3)
[20]. The control group (HD, for healthy donors) consisted in 15
anonymous healthy individuals who donated blood at the
Etablissement Franc¸ais du Sang (Paris, France).
Whole blood cytokine stimulation
A whole blood assay was developed to measure STAT5
phosphorylation in limiting samples from ICL patients with severe
lymphocytopenia. The assay was adapted from our previously
described protocol optimized for the measurement of IL-7
responses in PBMC from HIV-infected patients [36]. Briefly,
800 ml aliquots of heparinized blood were stimulated with 20 pM
or 2 nM recombinant human glycosylated IL-7 (Cytheris, Issy-les-
Moulineaux, France), or with 20 pM or 2 nM recombinant
human IL-2 (Chiron, Emeryville, CA), or with 10 nM recombi-
nant human TSLP (Peprotech, Rocky Hill, NJ). Blood was
stimulated for 15 min at 37uC, before fixation and red cell lysis
with the Lyse/Fix Phosflow buffer (BD Biosciences, San Jose, CA)
for 10 min at 37uC, according to the manufacturer’s instructions.
After centrifugation, cells were washed with cold PBS and
permeabilized by adding 90% ice-cold methanol drop by drop.
After 15 min incubation on ice, methanol-fixed cells were stored at
220uC until processing for intracellular labeling.
Intracellular phospho-specific labeling
Methanol-permeabilized cells were washed twice in ice cold
PBS and rehydrated in staining buffer (PBS, 4% FBS) for 45 min.
Cells were then simultaneously stained with antibodies to cell
surface markers (CD3, CD4, CD45RA, and CD25) and two
intracellular markers: the form of STAT5 phosphorylated at Y694
(pSTAT5) and the Treg specific factor Foxp3. The panel of
antibodies was validated to ensure that recognized epitopes
resisted methanol treatment and allowed the efficient measure-
ment of pSTAT5 within the Treg and conventional CD4+ T cell
subpopulations. Cells were stained with the following antibody
combination: CD4-PerCP, CD45RA-phycoerythrin-cyanin 7
(CD45RA-PECy7) and pSTAT5-Alexa Fluor 647 (pSTAT5-
AF647) from BD Biosciences; Foxp3-AF488 and CD3-allophyco-
cyanin-e Fluor 780 (CD3-APC-eF780) from eBioscience (San
Diego, CA); and CD25-PE from DAKO (Glostrup, Denmark).
Each experiment included an isotypic control where the pSTAT5-
specific antibody was replaced by an IgG1-AF647 antibody (BD
Biosciences). After staining for 45 min at 4uC, cells were washed
once in cold PBS and fluorescence was acquired on the same day
on a Facs Canto flow cytometer (BD, Franklin Lakes, NJ) using the
FacsDiva V software. Flow cytometry data were analyzed with the
FlowJo V8.8.6 software (Tree Star, Ashland, OR). The inducible
cytokine response (D%pSTAT5+) was measured by the difference
in the percentage of pSTAT5+ cells before and after cytokine
stimulation.
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Immunophenotyping and measurement of cytokine
receptor expression
Since antibodies to cytokine receptor chains IL-7Ra (CD127),
IL-2Rb (CD122), cc (CD132), and TSLPR did not give detectable
binding to methanol-permeabilized cells, a separate set of
experiments was carried out to evaluate expression of these
markers on unpermeabilized whole blood cells. Samples of 400 ml
heparinized whole blood were lysed with BD Pharm LyseTM
Buffer (BD Biosciences) for 10 min. at 37uC. After centrifugation
and washing, cells were resuspended in cell surface staining buffer
(PBS, 1% BSA, 10 nM sodium azide) and were labeled for 30 min
at 4uC with combinations of the following antibodies: CD122-PE,
CD132-PE, HLA-DR-PE, CD3-PerCP, CD4-PerCP and
CD45RA-PECy7 from BD Biosciences; CD4-FITC, CD25-
APC, CD127-APC-AF750, CD62L-APC-AF750 and CD3-APC-
eF780 from eBioscience; and TSLPR-PE from BioLegend (San
Diego, CA). Cells were either fixed directly in 1% paraformalde-
hyde, or permeabilized with a Fix/Perm buffer adapted to Foxp3
detection (eBioscience), labeled for 30 min with the Foxp3-AF488
antibody, washed and fixed in paraformaldehyde. Fluorescence
was acquired on a Facs Canto cytometer as described above.
Measurement of cytokines in plasma
IL-7 concentration was measured in plasma collected on
EDTA, using an ELISA immunoassay according to the manufac-
turer’s instructions (Quantikine HS human IL-7, R&D Systems).
IL-2 concentration was measured in plasma collected on EDTA,
using a bead-based immunoassay (Milliplex, from Merck Milli-
pore, Billerica, MA), according to the manufacturer’s instructions.
Statistical analyses
Analyses were performed with the Prism 5.0 software
(GraphPad Software, La Jolla, CA), using nonparametric statistical
tests in all cases. Differences in variables between groups were
analyzed with the Mann-Whitney U Test. Horizontal bars on data
plots indicate median values. Correlations were analyzed with
Spearman’s coefficient R. All significant differences between
groups (p,0.05) are reported on data plots.
Results
1 Increased immune activation in ICL
Eleven of the 15 ICL patients studied experienced at least one
infectious episode (Table 1). The spectrum of opportunistic
pathogens included fungi (Pneumocystis jiroveci, Aspergillus niger),
viruses (human papilloma virus, varicella zoster virus) and bacteria
(Nocardia brasiliensis), with a predominance of mycobacteria (M.
tuberculosis, M. avium, M. kansasii). The patients had a median age of
48 years [range: 18–70] and had been diagnosed with ICL for a
median duration of 20 months [1–191]. The degree of CD4+ T
cell depletion was variable (median CD4+ T cell count: 142/mm3
[16–294]) and did not strictly correlate with the severity of
symptoms. However, ICL patients with severe opportunistic
infections had CD4+ T cell counts ,200/mm3. Most ICL patients
(14/15) also had CD8+ T cell depletion, as indicated by a median
CD8+ T cell count of 103/mm3 [15–1134] and by a relatively
preserved CD4/CD8 ratio (median ratio: 1.28 [0.03–5.6]).
Whole blood phenotyping analyses showed a decrease in the
percentage of CD45RA+ CD4+ T cell population in ICL patients
as compared to healthy blood donors (Table 2; p = 0.0005).
Further analyses of T CD4+ subsets based on combination of the
CD45RA and CD62L markers confirmed a marked decrease of
the naive subset (CD45RA+ CD62L+; p,0.0005) and showed a
converse increase in the effector memory subset (CD45RA2
CD62L2; p,0.0005), while the central memory-like subset
(CD45RA2 CD62L+) showed no significant changes. Expression
of the activation marker HLA-DR was significantly increased in
CD4+ T cells of ICL patients (p,0.01; Table 2). A concomitant
decrease in expression of the alpha chain of the IL-7 receptor,
CD127, occurred in the same population (p,0.05). HLA-DR and
CD127 expression correlated negatively (RICL =20.51, p,0.05),
consistent with the decrease in CD127 being driven by immune
activation in ICL. Expression of the different chains of the IL-2
receptor, the alpha chain CD25, the beta chain CD122, and the
common cc chain CD132, did not show significant changes in the
ICL group. The last cytokine receptor chain analyzed, TSLPR, is
a cc-like protein that can associate with CD127 to form the TSLP
receptor. TSLPR is expressed at very low levels on human T cells
but can be induced upon TCR activation [37]. Interestingly,
TSLPR expression could be detected in memory CD4+ T cells
from ICL patients, as shown in a representative example (Fig. S1,
row C). The increase in TSLPR expression was highly significant
in the ICL group (p,0.005), even though the frequency of
TSLPR+ cells remained relatively low (median value: 2.7%; range:
1.2%–10.3%). Taken together, immunophenotyping of the CD4+
T cell population pointed to a series of changes consistent with
chronic immune activation in ICL, including a switch toward
more differentiated memory subsets, the induction of activation
markers (HLA-DR, TSLPR), and the downregulation of CD127.
Table 2. Immunophenotype of the CD4+ T cell population.
HD group
(n =15)
ICL group
(n=15) P value
% CD4+ in T CD3+ 68.3 (43.9–77.5) 47.1 (2.4–83.0) 0.03
In T CD4+:
% CD45RA+ 57.02 (28.6–
71.1)
24.4 (1.6–65.9) 0.0005
% CD45RA+ CD62L+ 55.2 (29.4–68.8) 21.0 (0.7–54.2) 0.0002
% CD45RA+ CD62L2 1.4 (0.2–4.9) 2.5 (0.2–11.7) 0.17
% CD45RA2 CD62L+ 31.7 (18.4–50.1) 36.0 (6.2–54.5) 0.50
% CD45RA2 CD62L2 11.9 (9.2–30.8) 39.8 (21.9–85.8) 0.0002
% HLA-DR 1.3 (0.34–3.6) 3.7 (0.5–7.3) 0.006
% CD127 78.3 (58.0–89.4) 72.4 (32.8–89.6) 0.027
% CD25 8.4 (4.6–12.7) 11.6 (5.6–43.7) 0.053
% Treg (Foxp3+ CD25hi) 4.1 (1.1–8.3) 6.0 (1.2–20.40) 0.051
CD132 MFI 220 (148–927) 261 (93–404) 0.61
% CD122 3.7 (1.1–14.8) 3.0 (1.52–16.6) 0.90
% TSLPR 1.1 (0.8–3.0) 2.8 (1.8–10.6) 0.0017
In T CD4+ RA2:
% HLA-DR 2.1 (0.6–5.3) 5.4 (0.6–8.5) 0.027
% CD127 77.8 (59.0–92.8) 72.6 (48.0–89.2) 0.092
% CD25 14.2 (4.9–20.9) 14.5 (6.4–43.7) 0.90
% Treg (Foxp3+ CD25hi) 6.4 (1.6–9.1) 6.0 (2.0–21.9) 0.60
CD132 MFI 225 (158–1054) 253 (91–399) 0.92
% CD122 5.0 (1.2–22.1) 3.6 (1.7–19.2) 0.47
% TSLPR 1.0 (0.6–2.3) 2.7 (1.2–10.3) 0.0009
The median and range are reported for each immunological parameter. P
values obtained by comparing the HD and ICL groups with the Mann-Whitney
U test are reported. HD: healthy donors; ICL: patients with Idiopathic CD4
Lymphocytopenia; MFI: mean fluorescence intensity.
doi:10.1371/journal.pone.0055570.t002
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It remained possible that increases in immune activation
markers resulted from changes in proportions of CD4+ T cell
subsets, considering that such markers have a physiologically
higher expression in the memory than in the naive compartment.
Therefore, we further compared activation marker expression
within the T CD4+ CD45RA2 memory compartment. HLA-DR
and TSLPR expression remained significantly increased in the
ICL group (p,0.05 and p,0.0005, respectively; Table 2) while
the decrease in CD127 expression lost significance (p = 0.09).
Thus, immunophenotype changes in ICL patient CD4+ T cells
resulted from both changes in differentiation patterns and in
immune activation status. Since the naive CD4+ T cell compart-
ment was virtually absent in a subgroup of ICL patients
(minimum: 0.7%), further analyses of cytokine responses focused
predominantly on the T CD4+ CD45RA2 memory population.
2 Decreased responses to IL-7 in ICL
Responses to IL-7 stimulation were evaluated by measuring the
degree of phosphorylation of STAT5 at tyrosine 694 by
intracellular labeling. Whole blood samples were stimulated with
either a low IL-7 dose (20 pM) close to the Kd of the receptor
[38,39] or with a high IL-7 dose (2 nM) that ensured full
occupancy of the receptor. Detection of phosphorylated STAT5
(pSTAT5) showed a dose-dependent response within the T CD4+
CD45RA2 memory population (Fig. 1A). Analysis of basal
pSTAT5 levels prior to stimulation showed low levels of
constitutive STAT5 activation that did not differ significantly
between groups (median percentage of pSTAT5+ cells: 0.65% in
HD; 0.89% in ICL; p$0.05; not shown). Low dose IL-7
stimulation induced variable responses in blood from healthy
donors, the percentage of pSTAT5+ memory CD4+ T cells
ranging from 0 to 48% (Fig. 1C). Responses in the ICL group
tended to be in the lower range (HD vs. ICL: p= 0.051). High
dose IL-7 stimulation induced a uniformly high percentage of
response in healthy donors (range: 90.1–96.8% pSTAT5+ cells),
consistent with a full occupancy of the receptor (Fig. 1D).
Interestingly, high dose IL-7 responses were significantly lower
in the ICL group (range: 64.4–95.6%; p= 0.01), with a subset of
ICL patients showing clear impairment of STAT5 activation
(example in Fig. 1B). pSTAT5 responses to high dose IL-7
correlated with absolute CD4+ T cell counts in ICL patients
(Fig. 1E, RICL = 0.69, p,0.005), suggesting that impaired IL-7
responses may play a role in the CD4+ T cell loss characteristic of
ICL. In addition, low IL-7 responses were associated with a low
total lymphocytes count (Fig. 1F, RICL= 0.61, p,0.05), pointing
to a general perturbation of leukocyte homeostasis in ICL.
Analysis of pSTAT5 responses in function of CD127 expression
showed a positive correlation between the two parameters in the
ICL group (Fig. 2A and 2B). The correlation was significant after
both high dose IL-7 stimulation (RICL = 0.74; p,0.005) and low
dose IL-7 stimulation (RICL = 0.57; p,0.05), suggesting the
physiological relevance of this finding over a wide range of IL-7
concentrations. These findings implicated the downregulation of
the IL-7 receptor as a probable cause for the low IL-7 responses in
ICL.
CD127 can be downregulated by its ligand, the IL-7 cytokine
[40], and circulating IL-7 concentration is known to increase in
situations of lymphopenia [22,23], raising the possibility that
chronic IL-7 stimulation in ICL may drive CD127 downregulation
and cause a desensitization of IL-7 responses. To explore this
notion, we measured IL-7 concentrations in the plasma of ICL
patients (Fig. 2C). Circulating IL-7 was indeed increased in ICL
patients as compared to healthy donors (p = 0.009), though we
noted that IL-7 levels showed a wide distribution in patients.
Circulating IL-7 did not correlate with the decrease in IL-7
responses measured in memory CD4+ T cells (Fig. 2D). The
concentration of IL-7 did not correlate either with CD127
expression (not shown) or with CD4+ T cell counts (Fig. 2E).
Thus, the increase in circulating IL-7 did not appear sufficient to
account for defective IL-7 responses in ICL.
IL-7-dependent signaling was also evaluated in the naive
CD45RA+ CD4+ T cell compartment, this analysis being limited
to patients for whom it was possible to collect a sufficient number
of events in the naive gate (ICL: n = 11). Responses to low dose IL-
7 (Fig. S2A) and high dose IL-7 (Fig. S2B) tended to be lower in
the ICL group than in healthy donors, though the differences did
not reach significance (p= 0.11 for low dose IL-7; p = 0.13 for high
dose IL-7). It should be considered, however, that patients with a
minimal naive CD4+ T cell population, and presumably a more
severe perturbation of CD4+ T cell homeostasis, had to be
excluded from this analysis. The correlations between IL-7
responses and CD127 expression in the naive CD45RA+ CD4+
T cell population reached significance at high dose but not at low
dose IL-7 stimulation (Fig. S2C and S2D). The responses of naive
CD4+ T cells to high dose IL-7 correlated with absolute CD4+ T
cell counts in ICL patients (Fig. S2E, RICL = 0.65, p,0.05),
emphasizing the relevance of impaired IL-7 responses in the loss of
CD4+ T cell homeostasis characteristic of ICL.
3 Decreased responses to IL-2 in ICL
An initial analysis of pSTAT5 induction in function of CD25
expression showed that IL-2 responses were highly dependent on
CD25 levels (see examples for one healthy donor and two ICL
patients in Fig. 3). Since regulatory T cells (Tregs) express
significantly more CD25 than conventional memory CD4+ T cells
(Memc), IL-2 responses were analyzed separately within the two
populations. The memory Treg subset (MTreg) was defined
according to Foxp3 and CD25 expression within the T CD4+
CD45RA- population (Fig. 4A). In a representative healthy donor,
MTregs responded as efficiently to low dose (20 pM) and high
dose (2 nM) IL-2 stimulation as measured by pSTAT5 induction,
consistent with a high expression of the high affinity IL-2 receptor
in this subset (Fig. 4A, middle panel). In contrast, the Memc subset
showed only partial response to low dose IL-2, while most Memc
cells responded to high dose IL-2 (Fig. 4A, right panel).
Interestingly, a small subset of MTregs appeared unresponsive to
IL-2 in ICL patient P12 (Fig. 4B, middle panel), while IL-2
responses appeared also decreased in the Memc population
(Fig. 4B, right panel).
When considering all study subjects, in vitro stimulation with
low dose IL-2 (20 pM) induced a high response rate in MTregs in
the HD group (median: 95.3% pSTAT5+ cells) that was
significantly decreased in the ICL group (median: 89.6%
pSTAT5+ cells, p,0.05) (Fig. 4C). Low dose IL-2 stimulation
led to a moderate response rate within the Memc subset, that was
comparable between the HD and ICL groups (p N.S., Fig. 4D).
Analysis of responses to high dose IL-2 (2 nM) confirmed the
defect within the MTreg subset of ICL patients (p,0.01, Fig. 4E)
and revealed an additional defect in the Memc subset (p,0.05,
Fig. 3F). Importantly, decreased IL-2 responses in Memc
correlated with decreased CD4+ T cell counts in the blood of
ICL patients (RICL= 0.63, p,0.05, Fig. 4G), suggesting that
defective IL-2 responses may contribute to the loss of CD4+ T cell
homeostasis.
IL-2 responses were measured in the naive CD45RA+ CD4+ T
cell population for patients who had sufficient cells available for
analysis (ICL: n= 10). The induction of pSTAT5 after 20 pM IL-2
stimulation was low in the naive subset, as expected, and did not
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Figure 1. Decreased IL-7 responses in ICL. (A) Example of pSTAT5 response to IL-7 stimulation measured in whole blood from a healthy donor.
The gating strategy to detect pSTAT5 induction by flow cytometry within the memory CD4+ T cell population, defined as CD3+ CD4+ CD45RA2
lymphocytes, is depicted. The percentages within the histogram plots indicate the fraction of pSTAT5+ cells after high dose IL-7 stimulation. A dose
dependent response is observed, with a higher pSTAT5 expression at high IL-7 dose (2 nM) than at low IL-7 dose (20 pM). (B) Example of decreased
pSTAT5 response to IL-7 stimulation in memory CD4+ T cells from ICL patient P3. (C) Induction of pSTAT5 after stimulation with low dose IL-7. The
inducible cytokine response (D%pSTAT5+) was measured by the difference in the percentage of pSTAT5+ cells before and after IL-7 stimulation in
memory CD4+ T cells. (D) Induction of pSTAT5 after stimulation with high dose IL-7. HD: healthy donors; ICL: patients with idiopathic CD4
lymphocytopenia. P values obtained with the Mann-Whitney U test are reported. (E) Correlation between pSTAT5 responses to high dose IL-7
stimulation and absolute CD4+ T cells counts in the blood of ICL patients. (F) Correlation between pSTAT5 responses to high dose IL-7 stimulation and
the total lymphocyte count in the blood of ICL patients. The Spearman correlation coefficient R and the corresponding P value are indicated.
doi:10.1371/journal.pone.0055570.g001
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differ significantly between groups (median D%pSTAT5+ cells:
2.9% in HD; 7.5% in ICL; p$0.05; not shown). High dose IL-2
responses in the naive subset did not differ either (median
D%pSTAT5+ cells: 34.6% in HD; 44.2% in ICL; p$0.05; not
shown). Thus, the impairment of IL-2 responses appeared
restricted to the memory CD4+ T cell population.
Correlation analysis between high dose IL-2 responses and
CD25 expression showed a positive association between the two
parameters in the Memc population (Fig. 5A, right). The
correlation was significant for ICL patients (RICL = 0.58;
p,0.05), suggesting that a relative decrease in CD25 expression
could impact IL-2 responses in ICL. Correlations were not
significant in the HD group, but reached statistical significance
when analyzing all study subjects together (RALL = 0.51 and
p,0.001 in Memc). In contrast, the lack of correlation between
CD25 expression and IL-2 responses in MTregs suggested that
CD25 expression was not a limiting factor in this subset, possibly
due to a constitutively high expression. Observing the distribution
of data points in Fig. 5A (left panel) suggested that, for comparable
CD25 expression, MTregs of ICL patients had lower IL-2
responses than MTregs of healthy controls. Thus, defective IL-2
responses in ICL could not be solely explained by a decreased
expression of CD25. To determine whether a high level of
circulating IL-2 may lead to a desensitization of IL-2 responses, we
measured IL-2 concentrations in the plasma of healthy donors and
of a subset of ICL patients (n = 7). We did not detect increased IL-
2 levels in the tested ICL patients (median values: 20.6 pg/ml in
HD; 11.8 pg/ml in ICL; P$0.05; not shown), suggesting that an
Figure 2. Correlation between IL-7 responses and CD127 expression. (A and B) The percentage of IL-7-induced pSTAT5+ cells within the
memory CD4+ T cell population is reported as a function of CD127 expression. (A) Responses to low dose IL-7 (B) Responses to high dose IL-7. HD:
healthy donors; ICL: patients with idiopathic CD4 lymphocytopenia. The Spearman rank correlation coefficient RICL computed for ICL patients is
reported. (C) Concentration of IL-7 in plasma measured by ELISA assay. (D) Lack of correlation between plasma IL-7 and pSTAT5 responses to high
dose IL-7 in memory CD4+ T cells of ICL patients. (E) Lack of correlation between plasma IL-7 and CD4+ T cell counts in ICL patients.
doi:10.1371/journal.pone.0055570.g002
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excess of IL-2 was unlikely to account for the impairment of IL-2
responses.
Interestingly, a positive correlation was detected between IL-2
and IL-7 responses (Fig. 5B), suggesting that common mechanisms
may perturb several cytokine systems in ICL. High dose IL-7 and
IL-2 responses correlated positively for ICL patients, both in
MTregs (RICL = 0.62; p,0.05) and in the Memc subset
(RICL= 0.74; p,0.005). Taken together, these findings showed
that ICL patients with impaired IL-2 responses tended to have also
weak IL-7 responses, which, combined together, may significantly
perturb CD4+ T cell homeostasis.
4 Compensatory increase in TSLP responses in ICL
We next evaluated STAT5 phosphorylation in response to high
dose TSLP stimulation (10 nM) in whole blood (examples in
Fig. 6A and Fig. 3, right column). The percentage of responder
CD45RA2 CD4+ T cells was low in the HD group (median
pSTAT5+ cells: 1.1% [0.6–2.8]), consistent with the known low
reactivity of human T cells to this cytokine [37,41] (Fig. 5B).
Intriguingly, TSLP responses were increased in memory CD4+ T
cells of ICL patients (2.57% [0.2–21.4]; p = 0.013). The increase
remained significant when the patient with a particularly high
TSLP response (patient P9: 21.4% pSTAT5+ cells) was excluded
from the analysis (p = 0.02), indicating that acquired TSLP
responsiveness was a frequent occurrence in ICL, even though
the percentage of responding cells remained generally low. TSLP
responses remained minimal in the naive CD45RA+ CD4+ T cell
compartment (not shown), suggesting that only memory cells could
become responsive to this cytokine.
Since CD127 expression was decreased rather than increased in
ICL, it was unlikely that this receptor chain accounted for the
changes in TSLP response. Indeed, CD127 expression did not
correlate with TSLP responses (p = 0.37). The other chain of the
receptor, TSLPR, showed a significantly higher expression in the
ICL group (Table 2, p,0.001), suggesting that it played a role in
the increased sensitivity of memory CD4+ T cells to TSLP.
However, there was no positive correlation between the two
parameters (Fig. 6C, p= 0.52), indicating that other parameters
than receptor expression influenced the reactivity of CD4+ T cells
to TSLP. Comparison of pSTAT5 responses to different cytokines
revealed an inverse correlation between TSLP and IL-7 responses,
which did not reach statistical significance in the ICL group alone
(p = 0.23) but was significant when considering all study subjects
(Fig. 6D, RALL =20.41, p,0.05). Given the shared receptor chain
and the similar functions of the two cytokines, this finding pointed
to a possible role for TSLP in compensating decreased IL-7
responses and maintaining minimal CD4+ T cell homeostasis.
Further analyses showed that TSLP responses correlated positively
with HLA-DR expression (Fig. 6E), both in ICL patients
(RICL = 0.59, p,0.05) and when considering all study subjects
together (RALL= 0.45, p,0.05). Thus, immune activation ap-
peared to promote the unusual sensitivity of CD4+ T cells to
TSLP. Taken together, these findings suggested the induction of a
TSLP-based homeostatic mechanism in situations of abnormal
immune activation and defective cc cytokine responses.
Discussion
This study provides evidence for altered cytokine responses in
ICL. The two major cc family cytokines involved in the control of
CD4+ T cell homeostasis, IL-7 and IL-2, induced suboptimal
STAT5 phosphorylation in memory CD4+ T cells of ICL patients,
which correlated with decreased CD4+ T cell counts. The defects
in IL-7 and IL-2 responses were partial but correlated together,
resulting in a combined defect that may significantly impact CD4+
T cell survival and renewal capacities, and thus may contribute to
ICL pathogenesis. Abrogation of IL-7-dependent signaling results
Figure 3. Cytokine responses in function of CD25 expression. Examples of pSTAT5 responses to IL-7, IL-2, and TSLP stimulation are shown in
the CD4+ CD45RA- T cell population for one healthy donor (HD-15) and two ICL patients (ICL-P3 and ICL-P12). The percentage of pSTAT5+ cells is
reported in the upper right corner of each dot plot. Plots in the first column represent non-stimulated cells (NS). Responses to low dose IL-2 were
highly dependent on the degree of CD25 expression (4th column). In contrast, IL-7 responses tended to be lower in the CD25hi population (2nd and
3rd columns), consistent with known properties of Tregs [36]. TSLP responses did not show a dependence on CD25 expression (6th column).
doi:10.1371/journal.pone.0055570.g003
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Figure 4. Decreased IL-2 responses in ICL. (A) Example of pSTAT5 response to IL-2 stimulation measured in whole blood from a healthy donor.
The Foxp3/CD25 gating used to defined memory Tregs (MTreg) and conventional memory CD4+ T cells (Memc) within the CD3+ CD4+ CD45RA2
population is reported (left plot). Histograms show pSTAT5 basal levels (light blue area) and pSTAT5 induction after stimulation with low dose IL-2
(blue line) or high dose IL-2 (orange area) within the MTreg (middle plot) and Memc (right plot) populations. The percentages within each plot
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in a SCID phenotype characterized by the lack of T cells and
profound immunodeficiency [24], while abrogation of IL-2-
dependent signaling leads to inflammation, multi-organ lympho-
cyte infiltrates, and autoimmunity in mice [33] and possibly in
humans [42]. Both immune deficiencies and autoimmune
manifestations have been reported in ICL [12], which appears
consistent with an impairment of both IL-7 and IL-2 systems. It is
relevant that Tregs showed decreased IL-2 responses in ICL,
which may limit their persistence and suppressive function [43]
and contribute to the abnormal immune activation characteristic
of the disease.
Importantly, ICL was not characterized by a general impair-
ment of STAT5 phosphorylation, as indicated by increased
responses to the cytokine TSLP. Rather, proximal defects in the
IL-2 and IL-7 signaling pathways likely account for the decreased
responses to these cytokines. We did not find evidence for altered
expression of the common receptor chain cc in CD4+ T cells of
ICL patients. In contrast, expression of the alpha chain of IL-7R,
indicate the fraction of pSTAT5+ cells after high dose IL-2 stimulation. Maximal response is already achieved at low IL-2 concentration in MTregs, while
a dose-dependent response is observed in Memc. (B) Example, of IL-2 responses in CD4+ T cells from an ICL patient. A small fraction of MTregs fail to
respond to IL-2 (middle plot), while a larger fraction of Memc cells appear unresponsive (right plot). (C to F) The inducible cytokine response
(D%pSTAT5+) was measured by the difference in the percentage of pSTAT5+ cells before and after IL-2 stimulation. HD: healthy donors; ICL: patients
with idiopathic CD4 lymphocytopenia. P values obtained with the Mann-Whitney U test are reported. (C) Low dose IL-2 response in MTreg; (D) Low
dose IL-2 response in Memc; (E) High dose IL-2 response in MTreg; (F) High dose IL-2 response in Memc. (G) Correlation between pSTAT5 responses of
Memc to high dose IL-2 stimulation and absolute CD4+ T cells counts in the blood of ICL patients. The Spearman correlation coefficient R and the
corresponding p value are indicated.
doi:10.1371/journal.pone.0055570.g004
Figure 5. Impairment of IL-2 responses correlate with lower CD25 expression and decreased IL-7 responses. (A) The percentage
pSTAT5+ cells induced after high dose IL-2 stimulation (2 nM) is reported as a function of CD25 expression in MTregs (left plot) and Memc (right plot)
populations. The mean fluorescence intensity (MIF) of CD25 is reported on the x axis. (B) Correlation between pSTAT5 responses to high dose IL-2 and
high dose IL-7 in MTregs (left plot) and Memc (right plot). HD: healthy donors; ICL: patients with idiopathic CD4 lymphocytopenia. The Spearman rank
correlation coefficient RICL computed for ICL patients is reported.
doi:10.1371/journal.pone.0055570.g005
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CD127, was downregulated, and clearly correlated with decreased
STAT5 phosphorylation after IL-7 stimulation (R=0.74). Chronic
immune activation is known to induce the internalization of
CD127 and its transcriptional repression [40,44], and thus may
underlie the defect in IL-7 responses in ICL. A similar
phenomenon occurs in HIV infection, where abnormal immune
activation leads to chronically low CD127 expression in memory
T cells and contributes to impaired IL-7 responses [36,45]. Of
note, a recently published study also reports an impairment of IL-7
and IL-2 responses in ICL patients [46], supporting the notion
that defective cytokine responses contribute to the loss of CD4+ T
cell homeostasis in ICL. In this study, decreased IL-7 signaling did
not correlate with CD127 downregulation in CD4+ T cells, even
though CD127 expression was decreased as compared to healthy
controls. Thus, additional factors may impair IL-7 signaling
independently of IL-7 receptor expression. One possibility may be
Figure 6. Induction of a compensatory TSLP response in ICL. (A) Examples of pSTAT5 responses to TSLP stimulation in one representative
healthy donor (left plot) and ICL patients P7 and P9 (middle and right plots). Whole blood was stimulated with TSLP 10 nM and evaluated for the
expression of phosphorylated STAT5 (pSTAT5) in memory CD4+ T cells. (B) pSTAT5 response after stimulation with high dose TSLP within the memory
CD4+ T cell population. The inducible cytokine response (D%pSTAT5+) was measured by the difference in the percentage of pSTAT5+ cells before and
after stimulation with 10 nM TSLP. (C) Lack of correlation between expression of the TSLPR receptor chain and TSLP responses. The inducible TSLP
response (D%pSTAT5+) cells within the CD3+ CD4+ CD45RA2 population is reported in function of TSLPR expression. Blue circles: healthy donors; red
squares: ICL patients. (D) Inverse correlation between IL-7 and TSLP responses. The inducible pSTAT5 responses to high dose IL-7 (x axis) and high
dose TSLP (y axis) with memory CD4+ T cells are plotted. (E) Positive correlation between HLA-DR expression and TSLP responses. The percentage of
HLA-DR+ cells (x axis) and the inducible TSLP response (y axis) within the memory CD4+ T cell population are plotted. HD: healthy donors; ICL: patients
with idiopathic CD4 lymphocytopenia. The Spearman rank correlation coefficient RALL computed for all study subjects is reported.
doi:10.1371/journal.pone.0055570.g006
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a desensitization of the STAT5 signaling pathway due to chronic
stimulation by high IL-7 concentrations, as suggested by Puronen
et al. [46]. However, the levels of IL-7 in plasma did not correlate
with the decrease of pSTAT5 responses in our ICL cohort,
suggesting that the increase in circulating IL-7 is not sufficient
either to account for the impairment of IL-7 signaling. Thus,
multiple factors, including chronic immune activation and
increases in circulating cytokines levels, may concur in impairing
the responsiveness of the STAT5 pathway. It was intriguing that
some ICL patients with very low CD4+ T cell counts did not show
an increase in circulating IL-7 (Fig. 2E), as would have been
predicted by the ‘IL-7 consumption’ model. The lack of IL-7
increase in a subset of ICL patients, which has also been reported
in the NIH ICL cohort [23], raises the possibility of a defective
production of this key homeostatic cytokine. It should be noted
that the levels of IL-7 measured in the circulation may not
necessarily reflect those found within lymphoid tissues, as
suggested by a recent study showing reduced IL-7 availability in
lymph nodes of patients with advanced HIV infection [47]. Thus,
it will be important in future studies to directly evaluate the
production of IL-7 by stromal cells within lymphoid organs of ICL
patients.
ICL patients showed an impairment of IL-2 responses that
affected both conventional memory CD4+ T cells and the Treg
population. The decrease in IL-2 signaling is of lower magnitude
than that seen for IL-7, but it could still be physiologically relevant
through its effect on Tregs, which are highly dependent on IL-2
for their homeostatic regulation. The mechanism for the
impairment of IL-2 responses remains to be elucidated, though a
low expression of CD25 may be a contributing factor in a subset of
ICL patients, given the correlation between these two parameters
in the Memc population. CD25 is considered as an activation
marker in conventional memory cells [48] and it is therefore
intriguing that CD25 expression is not increased in ICL patients,
in spite of ongoing chronic immune activation. Exploration of the
multiple transcriptional and post-transcriptional mechanisms that
regulate CD25 expression [49] may further inform on ICL
pathogenesis. CD25 expression may not be the only factor
involved in the impairment of IL-2 responses, since the two
parameters did not correlate in the MTreg population. Of note,
defective IL-2 responses in Tregs may have far reaching
consequences, considering that inactivation of IL-2 signaling is
known to inhibit Treg suppressive function and consequently to
increase immune activation [43]. Activation can in turn lead to
decreased CD127 expression and impaired IL-7 responses. Thus,
a defect in IL-2 response can perturb IL-7 responses, which may
explain the correlation between these two parameters in ICL.
The finding of perturbed IL-2 and IL-7 responses is compatible
with our previous observation for decreased CXCR4 expression in
ICL [20]. Cytokines of the cc family are major inducers of
CXCR4 [30–32] and decreased IL-2 and IL-7 responses are
expected to lower the expression of this chemokine receptor. As a
consequence, the loss of CD4+ T cell homeostasis in ICL may not
result only from lack of trophic and survival signals from cytokines,
but also from perturbed CXCR4-dependent trafficking, which
would impair T cell differentiation. Importantly, high amounts of
exogenous cytokine appear to reverse the CXCR4 expression
defect, as indicated by normalized CXCR4 levels at the surface of
circulating CD4+ T cells after IL-2 immunotherapy in three out of
four treated patients [20]. In this initial study, the only patient who
did not normalize CXCR4 expression levels also failed to increase
CD4+ T cell counts after IL-2 treatment and did not benefit
clinically from the therapy, with continued occurrence of multiple
opportunistic infections. Of note, this patient, denoted P9 in the
present study, showed the most severely impaired IL-2 responses in
vitro. Testing cytokine responses in vitro should be evaluated further,
to determine whether this assay may indeed have predictive value
and help clinicians devise immunotherapeutic approaches to treat
ICL. In this respect, it is relevant that IL-7 responses appeared less
defective than IL-2 responses for patient P9, raising the possibility
that IL-7 therapy may benefit this type of patient. Phase I/II
studies of IL-7 immunotherapy in lymphodepleted cancer patients
and HIV infected patients have demonstrated the capacity of this
cytokine to reconstitute both the naive and memory CD4+ T cell
pools and, importantly, to increase TCR repertoire diversity,
which should help restore adaptive responses to diverse pathogens
[50,51].
Naive CD45RA+ CD4+ T cells were severely depleted in ICL
patients, consistent with previous studies [5,12,26]. Analyses of
cytokine responses in this subset showed a trend for decreased IL-7
responses, but preserved IL-2 responses and an absence of
reactivity to TSLP. Thus, the remaining naive CD4+ T cells
were few but appeared to have relatively preserved functions. One
straightforward explanation for the loss of naive CD4+ T cells may
be their conversion to memory-like cells as a homeostatic response
to severe lymphopenia, as described in mouse models of T cell
depletion and in patients undergoing myeloablative therapies
[33,52]. Upon T cell depletion, increased availability of cc-
cytokines, in particular IL-7 and IL-15, and of self antigens
presented by dendritic cells can drive the conversion of naive cells
to a CD45RA-negative phenotype and promote their prolifera-
tion, in the absence of TCR stimulation by exogenous antigens.
The increase in CD4+ T cell proliferation observed in ICL
patients [12] suggests that conversion of naive cells to memory-like
proliferating cells is occurring in ICL, in spite of the suboptimal
responses to cc-cytokines. This homeostatic proliferation could
contribute to the immune activation characteristic of ICL, though
other mechanisms may also be at work. Direct consequences of
CD4+ T cell loss, such as the reactivation of opportunistic
pathogens, or microbial translocation due to the depletion of Th17
cells in the gut mucosa, likely contribute to chronic immune
activation in ICL, in a pattern comparable to that seen in HIV
infection [53]. Indeed, microbial translocation products can be
detected in the plasma of ICL patients [13]. The lower IL-2
responses in ICL patients may also fuel immune activation
through reduced Treg suppressive activity, as discussed above.
Thus, multiple mechanisms may concur in driving chronic
immune activation and exhaustion of the naive CD4+ T cell pool
in ICL.
TSLP responses were explored because this cytokine shows a
degree of functional redundancy with IL-7 [34,35,54]. Mouse
models have provided evidence for a contribution of TSLP to
CD4+ T cell development, which becomes apparent only in the
absence of IL-7 signaling [55]. TSLP also contributes to the
recovery of the CD4+ T cell pool after subletal irradiation, as
shown by a slower reconstitution in TSLPR knockout mice [55].
The role of TSLP in humans has been debated as freshly isolated
human T cells, in contrast to those of mice, do not respond to
TSLP stimulation [37,41]. Activation through the TCR can confer
a degree of TSLP responsiveness to human T cells maintained in
culture, though the levels of STAT5 phosphorylation remain lower
than those induced by IL-2 or IL-7 [37]. In contrast, TSLP
powerfully activate human dendritic cells and primes them to
induce Th2 responses, which is thought to promote allergic
conditions [34,35]. The detection of TSLP responses in CD4+ T
cells of ICL patients suggests that TSLP does play a role in human
T cell homeostasis. This is, to our knowledge, the first time that
physiological TSLP responses have been detected in freshly
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isolated human T cells. The inverse correlation with IL-7
responses points to a compensatory role for TSLP, which may
act as a second line homeostatic cytokine when the T cell pool is
severely depleted. The frequency of TSLP-responsive cells remain
relatively low in ICL, suggesting that TSLP responses alone are
unlikely to fully compensate for the impairment of IL-7 responses,
and possibly explaining why ICL patients remain lymphopenic.
These observations are consistent with findings in mouse models,
where TSLP functions become apparent in the absence of IL-7
signaling or in cases of lymphodepletion, but do not fully replace
IL-7 functions. It will be important to determine whether TSLP
responses are induced in other lymphopenic conditions, such as
HIV infection or bone marrow transplantation.
Expression of the activation marker HLA-DR correlated with
TSLP responses, suggesting that lymphopenia-driven immune
activation increased the sensitivity of CD4+ T cells to TSLP. One
mechanism is likely the upregulation of the TSLPR receptor
chain, which was significant in CD4+ T cells of ICL patients, and
which can be induced by TCR-dependent activation of human
CD4+ T cells [37]. However, it should be noted that immune
activation has an opposite influence on the second chain of the
receptor, since it causes the internalization of IL-7Ra/CD127
[40,44] These balancing influences may limit the amount of
functional heterodimeric TSLP receptor, and may help explain
why TSLPR expression did not simply correlate with TSLP
responses. Immune activation may also promote TSLP responses
at a step downstream of the receptor by facilitating the triggering
of signaling, for instance through increased Jak1 and Jak2 activity
[56,57], or through the blockade of negative regulators of cytokine
signaling such as SOCS proteins [58].
In conclusion, this study provides evidence for impaired IL-7
and IL-2 signaling in ICL, which likely contributes to the loss of
CD4+ T cell homeostasis characteristic of this rare disease. The
increase in TSLP responses reveals a new level of CD4+ T cell
homeostatic regulation that may mitigate the effect of impaired
responses to cc family cytokines. Understanding how cytokine
networks are perturbed in ICL may further inform on fundamen-
tal mechanisms of CD4+ T cell homeostasis and may help devise
immunotherapeutic approaches to restore CD4+ T cell counts and
functions.
Supporting Information
Figure S1 Detection of cytokine receptors by flow
cytometry. Representative examples of staining for IL-2, IL-7,
and TSLP receptor chains are shown for one healthy donor (HD,
left column) and one ICL patient (ICL, middle column). Negative
controls consisting in cells labeled with an isotype-matched
irrelevant antibody (IgG1 or IgG2a), or without antibody (no-
IgG) are shown in the right column. The plots are gated on the live
CD3+ CD4+ CD45RA- memory population. (A) Staining for
CD122/IL-2Rb and CD25/IL-2Ra. (B) Staining for CD132/IL-
2Rc and CD25/IL-2Ra. (C) Staining for TSLPR and CD127/IL-
7Ra.
(EPS)
Figure S2 IL-7 responses in naive CD4+ T cells of ICL
patients. (A) Induction of pSTAT5 after stimulation with low
dose IL-7. The inducible cytokine response (D%pSTAT5+) was
measured by the difference in the percentage of pSTAT5+ cells
before and after IL-7 stimulation in naive CD45RA+ CD4+ T
cells. (B) Induction of pSTAT5 after stimulation with high dose IL-
7. HD: healthy donors; ICL: patients with idiopathic CD4
lymphocytopenia. P values obtained with the Mann-Whitney U
test are reported. (C and D) The percentage of IL-7-induced
pSTAT5+ cells within the naive CD4+ T cell population is
reported as a function of CD127 expression. (C) Responses to low
dose IL-7 (D) Responses to high dose IL-7. (E) Correlation
between pSTAT5 responses to high dose IL-7 stimulation in naive
CD45RA+ CD4+ T cells and absolute CD4+ T cells counts in the
blood of ICL patients. The Spearman correlation coefficient R
and the corresponding P value are indicated.
(EPS)
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